Genetic susceptibility to end-stage renal disease

JR Schelling, L Zarif, A Sehgal, S Iyengar… - Current opinion in …, 1999 - journals.lww.com
JR Schelling, L Zarif, A Sehgal, S Iyengar, JR Sedor
Current opinion in nephrology and hypertension, 1999journals.lww.com
New methods have been developed to uncover the genotypes that result in complex
diseases. End-stage renal disease is a complex disease, without a simple correspondence
between genotype and phenotype. Both population-based and family-based
epidemiological studies and analysis of model organisms suggest that the pathogenesis of
end-stage renal disease may have a genetic component. A number of studies have
analyzed candidate nephropathy genes with little success, but recently several well …
Abstract
New methods have been developed to uncover the genotypes that result in complex diseases. End-stage renal disease is a complex disease, without a simple correspondence between genotype and phenotype. Both population-based and family-based epidemiological studies and analysis of model organisms suggest that the pathogenesis of end-stage renal disease may have a genetic component. A number of studies have analyzed candidate nephropathy genes with little success, but recently several well-designed studies of multiplex families with diabetic nephropathy have identified candidate nephropathy susceptibility loci. To date, kidney disease-oriented research has focused on effector mechanisms responsible for the initiation and progression of chronic renal disease. However, because end-stage renal disease is a complex disease, interruption of a single effector pathway is unlikely to result in significant therapeutic benefit. Further understanding of the pathogenesis of kidney disease and the development of new kidney disease therapies will require continued application of genetic and genomic tools to kidney disease research.
Lippincott Williams & Wilkins